Boyle, E. M., Leleu, X., Petillon, M., Karlin, L., Doyen, C., Demarquette, H., Royer, B., Macro, M., Moreau, P., Fostier, K., Marie‐Lorraine, C., Zarnitsky, C., Perrot, A., Herbaux, C., Poulain, S., Manier, S., Beauvais, D., Walker, B. A., Wardell, C. P., Vincent, L., Frenzel, L., Caillon, H., Susanna, S., Dejoie, T., Avet‐Loiseau, H., Mohty, M., Facon, T., & , (2019). daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial. British journal of haematology, 187, 319–327. http://access.bl.uk/ark:/81055/vdc_100094617029.0x00005e